| Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights |
Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected to begin by early 2026; commencing enrollment in prospective natural history study, CLARITY-FA, in Q2 2025 to serve as concurrent external control Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently enrolling patients in Cohort 3; interim clinical data update on track for second half of 2025 Redeployed $20 million to focus on clinical-stage programs; cash, cash equivalents and investments of $106.9 million expected to provide operational runway into 2027 NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today provided business updates across its portfolio and reported first quarter 2025 financial results. “Based on the highly encouraging clinical data shared to date, we believe LX2006 could be transformational and establish a new standard of care in FA cardiomyopathy,” said R. |
globenewswire.com |
2025-05-12 11:00:00 |
Czytaj oryginał (ang.) |
| Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement |
Lexeo Therapeutics, Inc. established further positive interim data from phase 1/2 SUNRISE-FA study using LX2006 for the treatment of patients with Friedreich's Ataxia Cardiomyopathy. Pivotal LXEO registration study of LX2006 for the treatment of patients with Friedreich's Ataxia expected to start in 2026, with data release possible in 2027. The global Friedreich's Ataxia market is projected to reach $3.49 billion by the end of 2034. |
seekingalpha.com |
2025-05-05 18:19:03 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting |
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its AAV manufacturing approach will be presented at the 28 th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 13-17, 2025 in New Orleans, LA. “The data being presented at ASGCT underscore the strength of our industry-leading capabilities in AAV manufacturing with high yield and high quality,” said José Manuel Otero, Chief Technical Officer of Lexeo Therapeutics. |
globenewswire.com |
2025-05-01 13:16:00 |
Czytaj oryginał (ang.) |
| Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials |
Lexeo Therapeutics, Inc. LXEO on Monday released interim data across all dose cohorts of LX2006 for Friedreich ataxia (FA) cardiomyopathy, a serious heart condition in FA patients with a rare, inherited neuromuscular disorder. |
benzinga.com |
2025-04-07 13:34:01 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study |
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study |
globenewswire.com |
2025-04-07 10:00:00 |
Czytaj oryginał (ang.) |
| Pharma Frenzy: Volatility Ignites Biotech Sector |
The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price surges in Tonix Pharmaceuticals NASDAQ: TNXP and Lexeo Therapeutics NASDAQ: LXEO. The biotech industry is known for its volatile price swings, often influenced by clinical trial results and regulatory decisions. |
marketbeat.com |
2025-03-25 11:10:16 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights |
Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI across participants with abnormal LVMI at baseline, frataxin expression to be evaluated for any increase from baseline rather than numerical threshold Interim update from cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial: observed 71% and 115% increases in PKP2 protein expression in first two post-treatment biopsies; first participant evaluated 6-months after dosing experienced 67% reduction in premature ventricular contractions (PVCs) Completed enrollment of cohort 2 of LX2020 HEROIC-PKP2 Phase 1/2 trial; interim clinical data update expected in second half of 2025 LX2020 has been generally well tolerated with no treatment-related serious adverse events to date Cash, cash equivalents and investments of $128.5 million expected to provide operational runway into 2027 NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today provided business updates across its portfolio and reported fourth quarter and full year 2024 financial results. “We are pleased to share further regulatory clarity for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, and we appreciate the continued partnership from the FDA on an accelerated approval pathway to support adults and children living with this devastating condition,” said R. |
globenewswire.com |
2025-03-24 09:00:00 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 43rd Annual J.P. |
globenewswire.com |
2025-01-07 09:30:00 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer |
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs. |
globenewswire.com |
2024-12-19 09:00:00 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results |
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial; initial clinical data including safety and biodistribution on track for late Q1 / early Q2 2025 Appointed Tolga Tanguler to Board of Directors, an accomplished biopharmaceutical executive with over 25 years of senior leadership experience Cash and cash equivalents of $157.0 million expected to provide operational runway into 2027 NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today provided business updates across its portfolio of programs and reported third quarter 2024 financial results. “We have made significant progress over the last few months across all our clinical stage programs, including reaching alignment with the FDA on registrational endpoints to support an accelerated approval pathway for LX2006. |
globenewswire.com |
2024-11-13 09:30:00 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference |
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's |
globenewswire.com |
2024-10-30 08:14:00 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference |
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that interim data from the ongoing Phase 1/2 trial (NCT03634007) of LX1001 have been selected as a late-breaking oral presentation at the Clinical Trials on Alzheimer's Disease (CTAD) conference taking place October 29 - November 1, 2024, in Madrid, Spain. The presentation will include new safety and biomarker data from four dose cohorts of LX1001, an AAVrh10-based gene therapy candidate designed to deliver the protective APOE2 gene into the central nervous systems of APOE4 homozygotes with Alzheimer's disease. |
globenewswire.com |
2024-10-22 11:30:00 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics to Participate in Upcoming Investor Conferences |
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Lexeo management will participate in corporate presentations and fireside chats at the following investor conferences: H.C. |
globenewswire.com |
2024-09-05 11:30:00 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights |
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures |
globenewswire.com |
2024-08-12 11:00:00 |
Czytaj oryginał (ang.) |
| Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further |
Lexeo Therapeutics, Inc. achieved positive results across two studies using LX2006 for the treatment of patients with Friedreich's Ataxia Cardiomyopathy; Clinically meaningful improvements observed in several cardiac biomarkers. The global Friedreich's ataxia market is expected to reach $3.39 billion by 2034. Additional interim results, along with cardiac biopsy assessment in FA patients with LX2006, expected at an upcoming medical conference presentation in Fall of 2024. |
seekingalpha.com |
2024-07-16 17:17:29 |
Czytaj oryginał (ang.) |
| Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data |
Interim data from an early-stage study shows that treatment with Lexeo's (LXEO) experimental gene therapy reduced signs of heart complications in patients with Friedreich's ataxia. |
zacks.com |
2024-07-16 16:05:29 |
Czytaj oryginał (ang.) |
| Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet |
U.S. stocks traded higher midway through trading, with the Nasdaq Composite rising more than 200 points on Monday. |
benzinga.com |
2024-07-15 16:05:30 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy |
Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline |
globenewswire.com |
2024-07-15 10:00:00 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors |
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and Chief Executive Officer of argenx SE, as an independent, non-executive director to its Board of Directors. Mr. Van Hauwermeiren is a seasoned biotech executive with over two decades of experience in both general management and business development across the life sciences and consumer goods industries. |
globenewswire.com |
2024-07-08 11:00:00 |
Czytaj oryginał (ang.) |
| What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock |
Lexeo Therapeutics, Inc. (LXEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-05-14 17:01:19 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights |
Closed an oversubscribed $95 million equity financing in March with Q1 2024 cash balance of $195.1 million at quarter-end, expected to provide runway into 2027 Completed in-license agreement with Cornell University for intellectual property rights, including current and future clinical data from an ongoing investigator-initiated trial of AAVrh.10hFXN (LX2006) to support regulatory discussions Interim readout of combined data set of LX2006 at multiple doses anticipated in mid-2024; Lexeo expects to provide analysis of natural history data and baseline characteristics of these study participants in advance of interim readout Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; data update from Cohort 1 on track for 2H 2024 NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today reported first quarter 2024 financial results and provided operational highlights. “We continue to make great progress in advancing our suite of gene therapy candidates. |
globenewswire.com |
2024-05-09 11:00:00 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics to Participate in Upcoming Investor Conferences |
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that company management will participate in fireside chats at the following investor conferences: The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 at 9:00 AM ETRBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14, 2024 at 11:00 AM ETBank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:40 AM PT The events will be webcast live under the News & Events tab in the Investors section of our website. Replays of the webcasts will be available on the website following the presentations. |
globenewswire.com |
2024-05-07 11:30:00 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy |
Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN (LX2006) to support regulatory discussions |
globenewswire.com |
2024-04-22 11:30:00 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy |
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LX2006, the company's AAVrh.10hFXN-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy. LX2006 is designed to deliver a functional frataxin gene to promote frataxin protein expression and restore mitochondrial function in myocardial cells. |
globenewswire.com |
2024-04-16 11:30:00 |
Czytaj oryginał (ang.) |
| Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off |
Lexeo Therapeutics, Inc. has results from its phase 1/2 SUNRISE-FA study, using LX-2006 for the treatment of patients with FA cardiomyopathy, expected in mid-2024. Results from all cohorts of phase 1/2 LEAD study, using LX-1001 for the treatment of patients with homozygous APOE4 AD, expected 2nd half of 2024. The global Alzheimer's Disease market is expected to reach $9.73 billion by 2030; It is said that between 15% to 25% of AD patients have this allele. |
seekingalpha.com |
2024-04-09 21:26:54 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing |
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced the closing of its previously announced private placement. The financing was co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel company), Eventide Asset Management, Novo Holdings A/S, Invus, Laurion Capital Management, Longitude Capital, Omega Funds and Woodline Partners LP for total gross proceeds of approximately $95.0 million. |
globenewswire.com |
2024-03-13 18:22:00 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights |
Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 |
globenewswire.com |
2024-03-11 09:42:00 |
Czytaj oryginał (ang.) |
| Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing |
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel company), Eventide Asset Management and Novo Holdings A/S. Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel company), Eventide Asset Management and Novo Holdings A/S. |
globenewswire.com |
2024-03-11 09:30:00 |
Czytaj oryginał (ang.) |